Key Safety Differentiators No IGF-1 elevation: AOD-9604 does not stimulate IGF-1, meaning it avoids risks such as organ/tissue overgrowth or acromegaly No glucose disruption: Clinical data shows it does not impair insulin sensitivity or worsen blood sugar regulation Comparable to placebo: In obesity trials, the incidence of adverse effects was similar to placebo groups, underscoring its tolerability Legal Status of AOD-9604 United States: AOD-9604 is not FDA-approved as a drug, dietary supplement, or weight loss therapy
As shown, the ferroptosis marker ACSL4 was induced in a dose-dependent manner with QNZ treatment, while SLC7A11 was inhibited in the A549 cell line (Fig
After six months, high-density lipoprotein cholesterol (HDL-C) and triglyceride (TG) levels were significantly increased in the low-risk group, while the low-density lipoprotein cholesterol (LDL-C)/HDL-C ratio decreased in the high-risk group, suggesting favorable lipid modulation
Pricing Information The ReadyRx Glutathione Injection Program is currently offered at an introductory rate, making it an accessible option for those beginning their wellness journey
31 , e1900928 (2019)
1 and 2 are also displayed
